Merck & Co., Inc. (MRK) operating KPIs
MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30242% above fair value
$146.33+5.40 (+3.83%)
Close on Oct 29, 2026Market cap $361.02BP/E 117.1Yield 2.24%
Merck merck & Co., Inc. — Related-Party Cost of Sales to Organon ($M) ($M)
Merck Form 10-Q / 10-K Organon Spin-Off Note
Latest, FY2022
404
Period ended Dec 31, 2022
Change on a year earlier
+107.2%
195 in FY2021
History
2 years
Since FY2021
Sources
1
Form 10-K (filed 2023-02-24)
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Merck & Co., Inc. — Related-Party Cost of Sales to Organon ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2022 | Dec 31, 2022 | 404 | +107.2% | Form 10-K (filed 2023-02-24) ↗ |
| FY2021 | Dec 31, 2021 | 195 | – | Form 10-K (filed 2023-02-24) ↗ |
Cite this data
StockData. (2026). Merck Merck & Co., Inc. — Related-Party Cost of Sales to Organon ($M) ($M), annual FY2021–FY2022 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/ogn_mrk_side_cos
See every metric in the Merck KPI table. Data updated Oct 26, 2026.